Osimertinib-13C, d3
Osimertinib-13C, d3 is the deuterium and 13C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.
Product Specifications
CAS Number
2254100-49-5
Product Name Alternative
AZD-9291-13C, d3; Mereletinib-13C, d3
UNSPSC
12352005
Target
EGFR
Type
Isotope-Labeled Compounds
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.14
Solubility
10 mM in DMSO
Smiles
CN1C=C(C2=NC(NC3=C(C=C(C(NC(C=C)=O)=C3)N([13C]([2H])([2H])[2H])CCN(C)C)OC)=NC=C2)C4=CC=CC=C41
Molecular Formula
C27 13CH30D3N7O2
Molecular Weight
503.62
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4 (9) :1046-61.; Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-D452310-5MG 5 mg
(13S,14R)-1,13-Dihydroxycanadinium, Inner Salt
Sign In for Pricing
View Details 
